01 / À propos

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.